Please login to the form below
Aliqopa
This page shows the latest Aliqopa news and features for those working in and with pharma, biotech and healthcare.
FDA clears Novartis’ new breast cancer drug Piqray
Three PI3K inhibitors have been approved for blood cancers – namely Gilead Sciences’ Zydelig (idelalisib), Bayer’s Aliqopa (copanlisib) and Verastem’s Copiktra (duvelisib) – but so far they have been unable to
Latest news
-
Novartis claims a rare win at ESMO for PI3K inhibitor class
Zydelig is among the existing PI3K inhibitors on the market. Three PI3K inhibitors have been approved for blood cancers – namely Gilead Sciences’ Zydelig (idelalisib), Bayer’s Aliqopa (copanlisib) and most recently
-
Novartis considers filings for PI3K drug in breast cancer
years and was recently joined on the market by Bayer’s Aliqopa (copanlisib), also for blood cancers.
-
Bayer bags speedy US approval for lymphoma drug Aliqopa
The FDA has approved Bayer's PI3K inhibitor Aliqopa, setting up a market showdown with Gilead Sciences' Zydelig in follicular lymphoma. ... Aliqopa (copanlisib) has been given a conditional green light as a third-line treatment for patients with relapsed
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
-
Principal Medical Writer
-
Varies on experience
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Senior Content Editor - Biotechnology
-
Salary TBC
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
-
Account Management
-
Competitive Salary Offered
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Pfizer helps fund biotech venture from former researchers at closed Kent facility
- CureVac expands COVID-19 vaccine trial protocol to include variant specification
- First dose of Pfizer/BioNTech vaccine reduces COVID-19 infection risk by 70%
- J&J looks ahead at potential flu therapy after approval of its COVID-19 vaccine
- New restrictions for AZ/Oxford COVID-19 vaccine despite EMA endorsement
- Lucid Group Bolster its Senior Leadership Team
- Live Webinar: Nanobiotechnology, Artificial Intelligence, and Virtual Care
- Opdivo improves survival in oesophageal cancer
- Keytruda shows significant and meaningfully improvement in kidney cancer
- Congress 2020 BC (before COVID-19)
- Shaping the Future of Medicine, Science, and Technology
- Live Webinar: Virtual Trials, Remote Care, & Cross-Border Collaboration: Ethical & Legal Challenges
PMHub
Accession
Accession was a born from a passion and a vision. A passion to harness the power of market access to...
Latest intelligence
- Virtual congresses: video thrilled the cardio tsar
- Chris Ross explores the key learnings from a year of virtual congresses...
- When Will We Be Back To Normal?
- The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
- How to tell your healthcare story.
- Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....
Quick links
Infographics
